NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
NewsRx | Free Newsletters
 
----------
------------
NewsRx on Facebook
-----
NewsRx Passes
Press Release Submissions
PR Login
-----
2008 Award Logo
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
-----
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.

Security by Verisign

Search Results for Bradmer Pharmaceuticals Inc


Filter Articles: Clinical News | Consumer News | Business News | All News | More Options

Results 1 - 20      Next >


 Refine Search
Display Mode: Context | Summary
Bradmer implements cash conservation plan
2009 MAR 17 ... Bradmer Pharmaceuticals Inc. (BMR.TSX), announced that it will implement a restructuring plan to conserve existing ...
Subject: Bradmer Pharmaceuticals Inc.
Price: $3.00
*
Bradmer provides clinical trial update and announces evaluation of strategic alternatives
2009 MAR 2 ... Bradmer Pharmaceuticals Inc. (BMR.TSX), provided an update today on the ongoing Phase III GLASS-ART Trial testing ...
Subject: Clinical Trial Research
Price: $3.00
*
Bradmer to repurchase up to 8.3 million of its common shares pursuant to a substantial issuer bid
2009 JUL 28 ... Bradmer Pharmaceuticals Inc. (TSX: BMR) ("Bradmer" or the "Corporation") announced that its Board of Directors ...
Subject: Bradmer Pharmaceuticals Inc.
Price: $3.00
*
Bradmer announces additions to Scientific Advisory Board
2007 DEC 24 ... Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of ...
Subject: Glioblastoma
Price: $3.00
*
Bradmer announces new additions to management team
2008 APR 14 ... Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of ...
Subject: Cancer Gene Therapy
Price: $3.00
*
Bradmer announces Phase II results published in newly diagnosed glioblastoma which demonstrate improved survival and support upcoming Phase III study
2008 MAR 10 ... Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of ...
Subject: Glioblastoma
Price: $3.00
*
Bradmer appoints Robert Tessarolo to Board of Directors
2008 APR 14 ... Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of ...
Subject: Bradmer Pharmaceuticals Inc.
Price: $3.00
*
Bradmer initiates enrollment in Phase III GLASS-ART Trial in primary glioblastoma multiforme
2008 AUG 4 ... July 23, 2008 - Bradmer Pharmaceuticals Inc. (TSX: BMR), a biopharmaceutical company dedicated to the development and ...
Subject: Glioblastoma
Price: $3.00
*
Bradmer issued patent in Europe for use of Neuradiab(TM) to treat lymphoma
2008 DEC 15 ... Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of ...
Subject: Glioblastoma
Price: $3.00
*
Bradmer Medical Isotope Supply for Phase III Trial Secure
2007 DEC 24 ... Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of ...
Subject: Bradmer Pharmaceuticals Inc.
Price: $3.00
*
Bradmer Pharmaceuticals provides an activity update
2007 SEP 10 ... the most recent news developments at Bradmer Pharmaceuticals. Report 1: Bradmer Pharmaceuticals Inc. (TSX: BMR) announced today that it has issued and sold an aggregate of 5,786,869 units, ...
Subject: Bradmer Pharmaceuticals
Price: $3.00
*
Bradmer receives FDA approval to proceed with Phase III clinical trial
2008 JUN 16 ... Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of ...
Subject: Cancer
Price: $3.00
*
Bradmer reports progression free survival data from previous Phase II glioblastoma multiforme trials
2008 JUL 28 ... Bradmer Pharmaceuticals Inc. (TSX: BMR), a biopharmaceutical company dedicated to the development and ...
Subject: Glioblastoma
Price: $3.00
*
Bradmer sponsors physician panel to raise awareness of brain cancer treatments
2008 NOV 17 ... Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of ...
Subject: Brain Cancer
Price: $3.00
*
Bradmer to present at the 10th Annual BIO CEO & Investor Conference
2008 FEB 18 ... Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of ...
Subject: Bradmer Pharmaceuticals Inc.
Price: $3.00
*
Bradmer to present poster on progression free survival and overall survival data from Neuradiab(TM) Phase II trials at Society for Neuro-Oncology Meeting
2008 DEC 1 ... Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of ...
Subject: Clinical Trial Research
Price: $3.00
*
Recent reports from Bradmer Pharmaceuticals provided an update
2007 SEP 10 ... the most recent news developments at Bradmer Pharmaceuticals. Report 1: Bradmer Pharmaceuticals Inc. (TSX: BMR) announced today that it has entered an agreement to issue 5,400,000 units of ...
Subject: Bradmer Pharmaceuticals
Price: $3.00
*

Results 1 - 20      Next >

-----------------------
Home | Free Newsletters | Products | Article Library | About Us | Contact | Privacy Policy | Search | Visit VerticalNews.com
Copyright © 2009 NewsRx		 PR Login